Category Archives: Biotech Letter

When Insiders Go Shopping, Pay Attention

In 1815, Nathan Rothschild made his legendary fortune buying British securities when they were deeply discounted after Waterloo. “Buy when there’s blood in the streets,” he allegedly said. That kind of contrarian wisdom has made fortunes across centuries. Two centuries later, I find myself applying this timeless principle to Moderna (MRNA). The biotech darling has […]

A Pharma Giant Built For The Long Haul

I was sitting in my 1946 Ercoupe at the Nevada airfield last weekend, waiting for clearance to take off for a quick joy flight, when my phone buzzed with a text from a longtime Concierge client. “What’s the deal with AbbVie (ABBV)?” he wanted to know. “Is it worth adding to my portfolio now?” The […]